 |
|
|
Paloma Pharmaceuticals, Inc. is an early stage drug development company focusing on pathologies with a vascular component including cancer, ocular diseases (macular degeneration and diabetic retinopathy), arthritis, fibrotic diseases (pulmonary fibrosis) endometriosis, osteoporosis and skin diseases (psoriasis and atopic dermatitis). Paloma owns the intellectual property relating to a series of novel, proprietary, small molecule drugs created through an integrated design platform incorporating proprietary, customized and industry standard computational tools that has therapeutic potential for the treatment of the foregoing diseases. These small molecule drugs, "Palomids", have shown significant activity in the test tube and in animal models of disease. In tumor "xenograft" (human tumors put into mice) animal models, Palomids have shown the ability to reduce the progression of cancer, to regress and, in some animals, to cure cancer. This activity is thought to work through the Palomids' ability to both damage the tumor and the tumor vessel, hence be able to kill the tumor directly and also to starve the tumor through the blood vessels that feed it. In ocular diseases, the Palomids are expected to improve vision by simultaneously inhibiting growth, reducing edema and hemorrhage, and, possibly, regress existing disease-causing ocular vessels. Palomids have shown activity in animal models of macular degeneration and diabetic retinopathy and in a retinal detachment animal model, elimination of retinal scar formation. For skin diseases, Palomids have been shown to inhibit keratinocyte proliferation and induce their apoptosis. As both psoriasis and atopic dermatitis display both aberrant angiogenesis and hyperplasia, the Palomids are expected to show efficacy in humans through two distinct mechanisms.
|
|
|
|
|
17 November 2008
AACR special conference in cancer research
 full
story
. . . . . . . . . . . . . . . . . . . . . . . . .
15 April 2008
American Association for Cancer Research
full
story
. . . . . . . . . . . . . . . . . . . . . . . . .
13 February 2008
VentureWire Lifescience
full
story
. . . . . . . . . . . . . . . . . . . . . . . . .
8 February 2008
The Association for Research in Vision and Ophthalmology
full
story
. . . . . . . . . . . . . . . . . . . . . . . . .
7 February 2008
10th International Symposium on Anti-angiogenic Agents
full
story
. . . . . . . . . . . . . . . . . . . . . . . . .
12 November 2007
IBC 5th Annual International Conference on Anti-angiogenesis
full
story
. . . . . . . . . . . . . . . . . . . . . . . . .
16 April 2007
IBC 4th International Conference on Ocular Anti-angiogenesis
full
story
| |
